Kwang Dong Pharmaceutical challenges to the obesity treatment market with the best selling drug ‘Contrave’

Published: 2015-08-11 13:06:05

Updated: 2015-08-11 13:06:05

Kwang Dong Pharmaceutical(President Sung-won Choi) will enter the obesity treatment market.

Kwang Dong Pharmaceutical announced on the 10^th that it has established the domestic contract to exclusively sell the obesity treatment new drug, Contrave, with an U.S. biopharmaceutical company, Orexigen Therapeutics.

As signing the contract with Orexigen and acquiring all the rights in domestic appro...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.